Risultati per: HCV prima durante e dopo la diagnosi: cosa deve fare il medico di medicina generale

Il 22 settembre si celebra la Giornata nazionale di informazione

La ricerca sulla comprensione e sulla gestione di questa malattia neurodegenerativa si apre ai fattori di protezione e allo screening con l’intelligenza artificiale

“Imparare a intercettare i primi segnali, spesso sottovalutati”

Le luci dell’Oms sulla Giornata per la sicurezza del paziente

Efficace in fase iniziale, con un’accuratezza fino al 98%

Anderloni (Aigo): “Contano gli stili di vita e diagnosi precoce”

Anderloni (Aigo): “Contano gli stili di vita e diagnosi precoce”

Caressa e Bergomi, in ogni campo fondamentale gioco di squadra

‘In realtà Elle ha seguito protocolli e rientra nel 60% dei casi senza ricadute’

Oncologa, ‘La medicina olistica non cura, in realtà Elle ha seguito protocolli e rientra nel 60% dei casi senza ricadute’

Capace di rilevare da foto del cervello le alterazioni genetiche

Chronic hepatitis C(CHC) related decompensated cirrhosis is associated with lower SVR-12 rates and variable regression of disease severity following direct-acting antiviral agents (DAAs). We assessed rates of SVR-12, recompensation (Baveno VII criteria), and survival in such patients.

All’interno dell’Ospedale Maggiore cerimonia per Micheletti

Introduction
Previous studies have shown that substantial percentages of emergency department (ED) patients in the USA recommended for HIV or hepatitis C (HCV) decline testing. Evidence-based and cost-effective interventions to improve HIV/HCV testing uptake are needed, particularly for people who inject drugs (PWIDs) (currently or formerly), who comprise a group at higher risk for these infections. We developed a brief persuasive health communication intervention (PHCI) designed to convince ED patients who had declined HIV/HCV testing to agree to be tested. In this investigation, we will determine if the PHCI is more efficacious in convincing ED patients to be tested for HIV/HCV when delivered by a video or in person, and whether efficacy is similar among individuals who currently, previously or never injected drugs.

Methods and analysis
We will conduct a multisite, randomised controlled trial comparing PHCIs delivered by video versus in person by a health educator to determine which delivery method convinces more ED patients who had declined HIV/HCV testing instead to be tested. We will stratify randomisation by PWID status (current, former or never/non-PWID) to permit analyses comparing the PHCI delivery method by injection-drug use history. We will also perform a cost-effectiveness analysis of the interventions compared with current practice, examining the incremental cost-effectiveness ratio between the two interventions for the ED population overall and within individual strata of PWID. As an exploratory analysis, we will assess if a PHCI video with captions confers increased or decreased acceptance of HIV/HCV testing, as compared with a PHCI video without captions.

Ethics and dissemination
The study protocol has been approved by the institutional review board of the Icahn School of Medicine. The results will be disseminated at international conferences and in peer-reviewed publications.

Trial registration number
NCT05968573.